Veeva Systems Inc. Share Price Target ‘$241.47’, now 14.8% Upside Potential

DirectorsTalk Interviews

Veeva Systems Inc. which can be found using ticker (VEEV) now have 24 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $270.00 and $200.00 calculating the average target share price we see $241.47. (at the time of writing). Now with the previous closing price of $210.27 this would imply there is now a potential upside of 14.8%. The day 50 moving average is $213.11 and the 200 day moving average is $202.61. The market capitalization for the company is 33.93B. The current share price for the company is: $209.96 USD

The potential market cap would be $38,967,399,440 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 65.41, revenue per share of $14.72 and a 5.01% return on assets.

Veeva Systems Inc. is a provider of industry cloud solutions for the global life sciences industry. The Company’s offerings span cloud software, data, and business consulting and are designed to meet the needs of its customers and their most strategic business functions from research and development (R&D) to commercialization. The Company’s industry cloud solutions for the life sciences industry are grouped into two major product families: Veeva Development Cloud and Veeva Commercial Cloud. Veeva Development Cloud includes application suites for the clinical, regulatory, and safety functions of life sciences companies, all built on its proprietary Veeva Vault platform. Veeva Commercial Cloud includes solutions for the sales, medical affairs, and marketing functions of a life sciences company. Its software offerings include Veeva CRM, Veeva Vault PromoMats, Veeva Vault Medical, and Veeva Crossix. Its data offerings include Veeva OpenData, Veeva Link, and Veeva Compass.

Share on:

Latest Company News

India’s smart meter rollout is building a broader digital grid opportunity

India’s smart-meter rollout is developing into a wider digital-grid ecosystem spanning connected hardware, communications, utility software, cybersecurity and energy analytics.

Genflow Biosciences links ageing science with MASH research

MASH gives Genflow Biosciences a defined opportunity to explore how its SIRT6-based gene therapy research could address metabolic liver damage, inflammation and fibrosis.

GCP Infrastructure reports 8.0% portfolio yield and stronger balance sheet

GCP Infrastructure Investments has reported a 98.60 pence net asset value, portfolio valuation of £810.4 million and further debt and asset sale updates.

Plus500 expands US trading offering with new Single Stock Futures

Plus500 has launched Single Stock Futures in the US, broadening customer access to CME Group-listed contracts and leading US stocks.

Clarkson reports record first-half profit and raises interim dividend

Clarkson Plc reported record first-half profit, lifted interim dividend and said full-year performance is expected to be materially ahead of market expectations.

Ilika plc reaches a commercial turning point as new markets emerge for Stereax and Goliath (video)

Dr Tom McColm of Morphose Capital Partners explains why the company may be approaching an important commercial inflection point.

    Search